UroGen Pharma Ltd. (URGN)
$36.58-4.39%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.8B
- Beta
- 1.58
- P/E (TTM)
- -18.47
- Short % float
- 17.98%
- Days to cover
- 9.9
- SI change
- +24.3%
- 1W
- -10.12%
- 1M
- -12.36%
- vs SPY 1W
- -9.14%
- vs SPY 1M
- -14.23%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 43
- VALUE
- 20
- GROWTH
- 23
- GARP
- 81
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC49.1%
REV YoY-
ROE81.8%
EPS YoY-
ROA-38.7%
GROSS91
OP-35
NET-52
[VALUATION]
P/E TTM-18.47
P/E FWD16.47
SECTOR PE20.48
INDUSTRY PE13.99
P/B-13.92
P/FCF-
EV/EBITDA-27.08
EV/EBIT-
PEG0.32
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO3.80
ND/EBITDA-
BETA1.58
Company news
FAQ
- What is LOPJLB’s current signal on URGN?
- LOPJLB’s latest quantitative signal on UroGen Pharma Ltd. (URGN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is URGN in?
- UroGen Pharma Ltd. (URGN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does UroGen Pharma Ltd. (URGN) do?
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladd…